Cargando…
NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
BACKGROUND: Early identification of cardiac dysfunction by non-invasive imaging in HER2-positive breast cancer patients treated with trastuzumab is challenging. In particular multigated acquisition (MUGA) scan, which is most widely used, is unable to detect subclinical cardiac changes. The use of N-...
Autores principales: | Bouwer, Nathalie I., Liesting, Crista, Kofflard, Marcel J. M., Sprangers-van Campen, Sylvia M., Brugts, Jasper J., Kitzen, Jos J. E. M., Fouraux, Michael A., Levin, Mark-David, Boersma, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048136/ https://www.ncbi.nlm.nih.gov/pubmed/32154011 http://dx.doi.org/10.1186/s40959-019-0039-4 |
Ejemplares similares
-
Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice
por: Bouwer, Nathalie I., et al.
Publicado: (2020) -
2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab
por: Bouwer, Nathalie I., et al.
Publicado: (2021) -
Die Biomarker BNP und NT‑proBNP
por: Oremek, G. M., et al.
Publicado: (2023) -
NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients
por: Blancas, Isabel, et al.
Publicado: (2020) -
Preoperative NT-proBNP and LVEF for the prediction of acute kidney injury after noncardiac surgery: a single-centre retrospective study
por: Wang, Jiaqi, et al.
Publicado: (2022)